

Marta Cipriani

Curriculum Vitae et Studiorum

Current position

2022-present **PhD student in Methodological Statistics**, *Sapienza University of Rome*, Italy.
Supervisor: Marco Alfò

Education

- May 2022 **Master's degree in Statistical Sciences - Major: Biostatistics**, *Sapienza University of Rome*, Italy, Thesis title: "*Modelli congiunti e pseudo-osservazioni in analisi di sopravvivenza*". Final vote: 110/110 cum laude.
Supervisor: Prof. Marco Alfò
- 2021 **Specialized training course**, *Sapienza University of Rome*, Italy.
Specialized training course in *Sustainability Sciences*, at the Faculty of Information Engineering, Computer Science and Statistics.
- 2021 **Foundational training course**, *Sapienza University of Rome*, Italy.
Foundational training course in *Sustainability Sciences*, at the Faculty of Information Engineering, Computer Science and Statistics.
- July 2019 **Bachelor's degree in Political Sciences**, *Roma Tre University*, Italy, Thesis title: "*Il modello di Cox applicato ad un'indagine su salute e longevità in Cina*". Final vote: 110/110 cum laude.
Supervisor: Prof. Francesco Lagona
- 2018-2019 **Erasmus+ Program**, *University Paris I Panthéon-Sorbonne*, France, Bachelor's course on Political Sciences.
Duration of study program: 6 months.

Work experience

- 2022-present **Biostatistical consultant**, *Fondazione GIMEMA Franco Mandelli ONLUS*, Rome, Italy.
Support in statistical methodology for clinical trials conducted by the Foundation.
- 2022 **Research collaborator**, *Fondazione GIMEMA Franco Mandelli ONLUS*, Rome, Italy.
With regards to the drafting of the thesis project, Scientific Collaboration Agreement with the 'Fondazione GIMEMA Franco Mandelli' regarding the GIMEMA AML 1310 trial.
- 2021 **Fellow**, *Sapienza University of Rome*, Italy.
Part-time collaboration fellowship.

Publications

- 2023 Martinelli G, Cipriani M, Marconi G, Guolo F *et al.*. Addition of venetoclax to FLAI induction chemotherapy (VFLAI) improves survival in patients with intermediate and high-risk AML vs FLAI and 3+7: A GIMEMA Italian cooperative analysis. *Journal of Clinical Oncology* (2023) 41 (16 suppl): 7013-7013.
- 2022 Piciocchi A, Messina M, Cipriani M *et al.*. The Addition of Venetoclax to Induction Chemotherapy in No Low-Risk AML Patients: A Propensity Score-Matched Analysis of the Gimema AML1718 and AML1310 Trials. *Blood* (2022) 140 (Supplement 1): 137–138.
- 2022 Tadesse F, Gebremedhin A, Abubeker A, Piciocchi A, Cipriani M *et al.*. Health-Related Quality of Life and Financial Burden of Ethiopian Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors. *Blood* (2022) 140 (Supplement 1): 5264–5265.

Computer skills

Base SAS
Avanzate R, \LaTeX , Office

Language skills

Italiano **Mother tongue**
Inglese **Advanced**
Francese **Advanced**
Spagnolo **Intermediate**